Loading
Sentiment · FY2026 Q1
What companies say about each other on earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“a couple of the large top 20, for example, were on IQVIA. Okay. Those are going on over to Veeva.”
Veeva flagged competitive takeaways in CRM, with a couple of top-20 pharma customers migrating off IQVIA onto Veeva, a negative read-through for IQVIA's CRM franchise.
“This partnership with IQVIA is a very positive macro-level trend for the business, especially on the commercial side.”
Veeva describes its interoperability partnership with IQVIA as a positive macro trend benefiting both its data and software businesses, signaling constructive collaboration between the former rivals.
“We still compete with IQVIA in the areas of things like reference data, our open data product, our Compass product, things like that.”
Veeva continues to compete with IQVIA in reference and open data and its Compass product, while noting IQVIA exited pharmaceutical CRM after Salesforce entered the market.
“We partner in many, many areas, and we compete in some.”
Veeva and IQVIA resolved their roughly ten-year dispute; IQVIA data (previously barred from Veeva Network and Nitro) is now permitted and the two now partner broadly in customers' interest.
“Health care leaders, IQVIA, and Lumenon. And Mayo Clinic as well as ARC and Institute are using NVIDIA Corporation AI to speed drug discovery enhance genomic research, and pioneer advanced health care services with generative and agentic AI.”
IQVIA is using NVIDIA AI to speed drug discovery and genomic research, part of a broader healthcare adoption push.
“IQVIA is out of the game, their product sunset.”
Veeva management says IQVIA has effectively exited CRM competition after sunsetting its competing product.
“we do believe IQVIA data is directionally aligned. It's just some accounts, some channels are not represented in IQVIA, as you well know, so they're not reflected in the data”
Gilead characterizes IQVIA's script data as directionally aligned but incomplete for tracking the new Yeztugo launch, noting coverage gaps in IQVIA's dataset.
“I think Pfizer and maybe some others have talked about using AI in terms of trial efficient, improving trial efficiency.”
An analyst cites Pfizer publicly discussing AI to improve clinical-trial efficiency, a read-through on large-pharma AI adoption relevant to CRO demand.
“enhancing our capabilities in patient solutions and payer analytics with the acquisition of Federate Technologies in the fourth”
IQVIA acquired Federate Technologies to strengthen its patient-solutions and payer-analytics capabilities.
| Analyst | Firm | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Shlomo Rosenbaum | Stifel | 6 (17%) |
| Elizabeth Anderson | Evercore ISI | 5 (0%) |
| Dave Windley | Jefferies |
“expanding our science management organization with the acquisition of -- next Oncology, a network of specialized sites serving patients enrolled in early-stage oncology trials.”
IQVIA acquired Next Oncology, a network of early-stage oncology trial sites, to expand its clinical site capabilities.
“Cedar Gate itself was a great opportunity. It's basically, it transforms happier data into insights for improved patient outcomes and provide analytics to payers.”
IQVIA acquired Cedar Gate to scale its US payer/provider analytics platform, a value-based-care analytics business.
“we announced a partnership with NVIDIA, which with whom we have been working for over a year to build agents into our workflows, both in clinical and commercial”
IQVIA has been building AI agents with NVIDIA for over a year across clinical and commercial workflows, underscoring NVIDIA's traction in healthcare AI infrastructure.
“We announced the strategic collaboration with Amazon Web Services namely AWS as our preferred agentic car provider to accelerate the industry's digital transformation.”
IQVIA named AWS its preferred agentic-AI cloud provider for life sciences, a positive read-through for AWS's enterprise AI positioning in healthcare.
“And most of that is one acquisition called NEXT Oncology, which is an SMO specialty in oncology, very attractive business.”
IQVIA acquired NEXT Oncology, a site-management organization specializing in Phase I oncology trials, as part of ~$485 million of quarterly acquisition spend to build its R&D Solutions/SMO capabilities.
“I'm just asking also because not just Medpace also reported with some better numbers.”
An analyst points to peer CRO Medpace also reporting improved results as evidence of a broader recovery in clinical-research demand; IQVIA management pushed back that the two companies rarely compete head-to-head for the same work.
“our recently announced strategic collaboration with Sarah Cannon Research Institute, one of the nation's leading oncology research hospital network”
IQVIA announced a strategic collaboration with the Sarah Cannon Research Institute oncology hospital network aimed at accelerating trial activation and recruitment in community oncology settings.
“This collaboration develops custom-built AI agents using NVIDIA technology designed to streamline processes, enhance workflows and accelerate insights across the life sciences ecosystem.”
IQVIA is collaborating with NVIDIA to build custom AI agents for life-sciences workflows, with the work showcased at NVIDIA's flagship European conference as an example of leading-edge AI agentification.
“You may recall we announced our collaboration with NVIDIA earlier in the call. We are progressing as planned to deploy highly specialized industry AI agents.”
IQVIA is deploying AI agents across its business in collaboration with NVIDIA, supporting productivity gains in commercial, real-world, and R&DS segments.
“You saw the recent announcement of our collaboration with NVIDIA to transform healthcare and life sciences through advanced agentic AI solutions.”
IQVIA highlights a new AI collaboration with NVIDIA to embed agentic AI agents into its clinical and commercial workflows.
| Eric Coldwell | Robert W. Baird | 4 (25%) |
| Justin Bowers | Deutsche Bank | 4 (0%) |
| Mike Ryskin | Bank of America | 3 (33%) |
| Jack Meehan | Nephron Research | 3 (0%) |
| Jailendra Singh | Truist Securities | 2 (50%) |
| Ann Hynes | Mizuho Securities | 2 (50%) |
| Jeff Garro | Stephens | 2 (0%) |
| Firm | Analysts | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Stifel | 1 | 6 (17%) |
| Evercore ISI | 1 | 5 (0%) |
| Jefferies | 1 | 4 (0%) |
| Deutsche Bank | 1 | 4 (0%) |
| Robert W. Baird | 1 | 4 (25%) |
| Bank of America | 1 | 3 (33%) |
| Leerink Partners | 3 | 3 (0%) |
| Nephron Research | 1 | 3 (0%) |
IQVIA capped a strong 2025 with Q4 revenue above guidance at 10.3% reported growth and adjusted EPS of $3.42, up 9.6% year-over-year, while R&DS bookings continued accelerating above $2.7 billion with 7% year-over-year growth. Full-year revenue grew approximately 6%, and the organizational simplification to two segments reflected the evolving business structure. Initial 2026 guidance projected 5.2-6.4% revenue growth to $17.2-$17.4B and EPS of $12.55-$12.85, with the Cedar Gate acquisition and EBP funding recovery supporting an improving industry backdrop.
Demand | Revenue Growth | Margin | Competitive Dynamics | Cloud & AI | Pricing | Cost Pressure | Regulation Policy | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 5 | 1 | 2 | 1 | 1 | 2 | 1 | |
| 2025Q1 | 5 | 2 | 2 | 2 | 2 | 1 | ||
| 2025Q2 | 7 | 4 | 2 | 4 | 1 | 1 | 2 | |
| 2025Q3 | 4 | 3 | 1 | 2 | 2 | 1 | ||
| 2025Q4 | 2 | 1 | 1 | 4 | 1 | |||
| 2026Q1 | 5 | 2 | 3 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Demand | 5 | 5 | 7 | 4 | 2 | 5 |
| Revenue Growth | 1 | 2 | 4 | 3 | 2 | |
| Margin | 2 | 2 | 2 | 1 | 1 | 3 |
| Competitive Dynamics | 1 | 2 | 4 | 2 | 1 | 1 |
| Cloud & AI | 1 | 2 | 4 | |||
| Pricing | 1 | 1 | 1 | 1 | ||
| Cost Pressure | 2 | 2 | ||||
| Regulation Policy | 1 | 1 | 2 |
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
IQV IQVIA | 7 | +8.4% | |
| A Agilent Technologies | 8 | +10.0% | |
| CRL Charles River Laboratories | 4 | +1.2% | |
| DGX Quest Diagnostics | 9 | +9.2% | |
| DHR Danaher Corporation | 7 | +3.7% | |
| IDXX Idexx Laboratories | 8 | +14.3% | |
| LH LabCorp | 8 | +5.8% | |
| MTD Mettler Toledo | 7 | +7.2% | |
| RVTY Revvity | 5 | +7.0% | |
| TMO Thermo Fisher Scientific | 7 | +6.2% | |
| WAT Waters Corporation | 9 | +91.5% |